



...For a Better World

Suite 1102 – 44 Victoria Street

Toronto, ON, M5C 1Y2

Tel: (416) 304-9935

Website: www.maticaenterprises.com

FOR IMMEDIATE RELEASE

MATICA REPORTS ON SITE INSPECTION OF DORVAL FACILITY

August 25, 2017 – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to report that Company management has completed a site visit at the Dorval, Quebec medical marijuana facility. Management of Matica were given a tour of the work site earlier this week by the general contractor, ICORE Construction.

Significant progress towards completion of the project is being made involving major upgrades of numerous systems. During our visit, plumbing, waste water and underground systems were being completed and inspected. The systems being installed are maximum capacity systems with interceptors designed to recover all types of solids to enhance sanitation through efficient prevention of clogged waste lines. The system design is an environmentally friendly green system which will prevent solids from entering municipal waste facilities. Lessening the impact on the environment is a major priority for Matica.

The redesign and construction of the extended capacity vault is underway and nearing completion. External cameras have been installed as part of the overall security system. The electrical system is also being upgrading with a backup generator which will supply power to the entire facility in the event of a power outage.

The plans for the HVAC system have been refined. As Matica is committed to producing the highest quality product, management has commissioned a state of the art custom built climate control system. Management feels that the added cost will be outweighed by the product quality and consistency that the climate controlled environment will produce. Installation of the HVAC is expected to commence in September.

Matica Enterprises CEO, Boris Ziger states, “A busy work site is a thing to behold. We are very excited that the build out is going ahead very smoothly and is on schedule to be completed in November.”

During this latest trip to Quebec, Matica management also toured the premises of a second late stage application under the Access To Cannabis for Medical Purposes Regulation (“ACMPR”) in Quebec as part of the ongoing due diligence. In a July 20th, 2017 news release Matica announced a letter of intent to acquire a majority stake in a second 10,000 square foot growing facility located in an industrial park in Saint-Laurent, Quebec.

About Matica

Matica has an agreement with RoyalMax Biotechnology Canada Inc. (“RoyalMax”) for Matica to become a majority owner (70%) of the late stage applicant under ACMPR. Matica and RoyalMax are diligently working to complete the build out of the 10,000 square foot facility in Dorval Quebec.

For more information on Matica please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

/s/Boris Ziger

Boris Ziger, CEO & Chairman

The Company's filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, Chief Executive Officer, at:

Telephone: 416-304-9935

E-mail: info@maticaenterprises.com

Website: www.maticaenterprises.com

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.

The CSE has not reviewed, approved or disapproved the content of this press release.